Silo pharma expands intellectual property portfolio with provisional patent filing for innovative spc-15 combination treatment

Spc-15 combination treatment shows enhanced efficacy in combating stress-induced psychiatric disorders sarasota, fl, feb. 18, 2025 (globe newswire) -- silo pharma, inc. (nasdaq: silo) (“silo” or the “company”), a developmental stage biopharmaceutical company focused on novel therapeutics and drug delivery systems, today announced the filing of a provisional patent application with the u.s. patent and trademark office (uspto) for its lead asset spc-15. silo currently has patents issued and numerous expanded patent applications pending for spc-15, a technology that was originally licensed through a collaboration with columbia university.
SILO Ratings Summary
SILO Quant Ranking